Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

• Published in: The New England journal of medicine Vol. 391; no. 2; pp. 109 - 121
• Main Authors: Perkovic, Vlado, Tuttle, Katherine R., Rossing, Peter, Mahaffey, Kenneth W., Mann, Johannes F.E., Bakris, George, Baeres, Florian M.M., Idorn, Thomas, Bosch-Traberg, Heidrun, Lausvig, Nanna Leonora, Pratley, Richard
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 11.07.2024
• Subjects: Aged; Albumin; Antidiabetics; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular Diseases - mortality; Cardiovascular Diseases - prevention & control; Chronic Kidney Disease; Clinical Medicine; Clinical Medicine General; Creatinine; Death; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Nephropathies - etiology; Diabetic Nephropathies - mortality; Dialysis; Double-Blind Method; Endocrinology; Epidermal growth factor receptors; Female; Glomerular filtration rate; Glomerular Filtration Rate - drug effects; Glucagon-Like Peptide-1 Receptor Agonists - administration & dosage; Glucagon-Like Peptide-1 Receptor Agonists - adverse effects; Glucagon-Like Peptide-1 Receptor Agonists - therapeutic use; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - pharmacology; Glucagon-Like Peptides - therapeutic use; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Hypothesis testing; Injections, Subcutaneous; Kidney diseases; Kidney transplantation; Laboratories; Male; Middle Aged; Nephrology; Placebos; Renal failure; Renal Insufficiency, Chronic - etiology; Renal Insufficiency, Chronic - mortality
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2403347

In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function.